[Metoprolol in the treatment of essential hypertension].
In the review the basic studies devoted to researching of effectiveness of metoprolol in treatment of essential hypertension and also influence of this drug in the prognosis in this group of patients, are summarized. The specification on pharmacokinetic properties of the drug is shown. Outcomes of two studies (BCAPS and ELVA) devoted to influence of metoprolol on progression of atherosclerosis in patients with the risk factors are explained. The outcomes of these trials have confirmed, that the long-term therapy with metoprolol is one of the factors retentive atherosclerosis progression and allow more precisely to judge about mechanisms of positive influence of metoprolol therapy on the prognosis of the patients with cardiovascular diseases.
Minushkina
L O
LO
Presidential Medical Center of Russia; ul. Marshala Timoschenko 15, 121356 Moscow, Russia.
Sidorenko
B A
BA
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001161:Arteriosclerosis / Q000188:drug therapy / Q000517:prevention & control; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008790:Metoprolol / Q000494:pharmacology / Q000627:therapeutic use*; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D008790:Metoprolol